more_reports

Biopharma Advances High-Impact, First-of-Its-Kind Neuroreparative Drug

  ()
NervGen Pharma Corp. (NGEN:TSX.V; NGENF:OTCQX) drug produced sustained neurologic and functional gains in chronic tetraplegia, positioning it for pivotal Phase 3 development.
Tags: Biotechnology / Pharmaceuticals

New York Healthcare Technology Co. Discovers Scalable Behavioral Health Breakthrough

  ()
DarioHealth Corp.'s (DRIO:NASDAQ) study showed measurable workplace productivity and cognitive function improvements in 1,254 users within weeks, boosting growth potential.
Tags: Life Sciences Tools & Diagnostics

California Biopharma Co. Uncovers Massive Oncology Breakthrough

  ()
Nurix Therapeutics Inc. (NRIX:NASDAQ) new cancer pipeline data highlights powerful targeted protein degradation advances, with analysts projecting 92% upside potential.
Tags: Biotechnology / Pharmaceuticals

Brisbane Biotech Showcases Degrader Pipeline Advantages at AACR

Research Report
  ()
Nurix Therapeutics (NASDAQ: NRIX) recently showcased AACR presentations that highlighted the mechanistic superiority of the company's protein degrader platform and preclinical data across key pipeline assets, NX-1607, NRX-4972.
Tags: Biotechnology / Pharmaceuticals

AI-Designed Cancer Drug Shows In Vivo Results, Brain Penetration

  ()
Rakovina Therapeutics Inc. (RKV:TSX.V) reported new preclinical data across two oncology programs at the AACR Annual Meeting, including ATR-mTOR inhibitor efficacy and kt-3283 formulation progress.
Tags: Healthcare ServicesBiotechnology / Pharmaceuticals

Asceniv Growth, Margin Expansion, and Pipeline Optionality Drive Price Target

Research Report
  ()
Canaccord Genuity initiates coverage of ADMA Biologics Inc. (ADMA:NASDAQ), citing Asceniv's differentiated hyperimmune IVIG profile, accelerating margins from yield enhancement, and an underappreciated pipeline.
Tags: Biotechnology / Pharmaceuticals

Genetic Medicines Co. Reveals Transformative 'Only-of-Its-Kind' AAV Therapy Milestone

  ()
MeiraGTx Holdings Plc (MGTX:NASDAQ) reports 3-year gene therapy results, secures US$100M funding, and advances late-stage pipeline, signaling major commercial potential.
Tags: Biotechnology / PharmaceuticalsRegenerative Medicine

Company Wins Back Promising Eye Disease Drug and Eyes Two Product Launches by 2028

Research Report
  ()
MeiraGTx Holdings plc. (MGTX:NASDAQ) reported three-year durability data for AAV-hAQP1 in radiation-induced xerostomia, the reacquisition of filing-ready XLRP asset bota-vec from Johnson & Johnson, and a US$100M, according to an H.C. Wainwright research note.
Tags: Biotechnology / Pharmaceuticals

Massachusetts Biotech Co. Faces Major Melanoma Drug Setback

  ()
Replimune Group Inc.'s (REPL:NASDAQ) RP1 melanoma therapy hits FDA rejection, raising uncertainty around approval timelines and future market potential.
Tags: Biotechnology / Pharmaceuticals

Biotech Firm Advances Voice-Based Intoxication Tech Aiming to Revolutionize Medical Diagnostics

  ()
MindBio Therapeutics Corp.'s (MBIO:CSE; MBQIF:OTCQB; WF6:Frankfurt) AI voice model analyzes 140+ biomarkers, targeting non-invasive impairment screening.
Tags: Biotechnology / PharmaceuticalsLife Sciences Tools & Diagnostics

MA Biotech Co. Downgraded to Sell After Second FDA CRL for RP-1 Melanoma BLA

Research Report
  ()
H.C. Wainwright downgraded Replimune Group (REPL:NASDAQ) to Sell after the FDA issued a second Complete Response Letter for the RP-1 plus Opdivo BLA in anti-PD1 failed melanoma.
Tags: Biotechnology / Pharmaceuticals

What Do Analysts Think About the Biopharma Set on Transforming Psychiatry

  ()
Alto Neuroscience Inc. (ANRO:NYSE) is a clinical-stage biopharmaceutical company focused on transforming psychiatry through novel drug candidates.
Tags: Biotechnology / Pharmaceuticals

Canadian Biotech Co. Appoints Elite Regulatory Expert for Chile Expansion

  ()
MindBio Therapeutics Corp. (MBIO:CSE; MBQIF:OTCQB; WF6:Frankfurt) appoints Chilean policy leader Felipe Leyton for the mining rollout of its AI impairment detection tech.
Tags: Medical DevicesBiotechnology / PharmaceuticalsLife Sciences Tools & Diagnostics

California Biotech Co. Advances Depression Drug Breakthrough

  ()
Alto Neuroscience Inc. (ANRO:NYSE) pivots after mixed trial results, targeting treatment-resistant depression with analyst support and major market growth potential.
Tags: Biotechnology / Pharmaceuticals

San Francisco Pharma Co.'s HORIZON Phase 2 Data Validates APOL1 Path to Pivotal Trial

Research Report
  ()
H.C. Wainwright reiterated its rating and price target on Maze Therapeutics (MAZE:NASDAQ), following KOL calls that validated the HORIZON Phase 2 dataset as biologically coherent, confirmed the diabetic cohort signal as drug-attributable proof of concept, and outlined a clear path to pivotal trials.
Tags: Biotechnology / Pharmaceuticals

Name Change, Share Consolidation, and US Clinic Strategy Signal Shift Toward Alzheimer's Diagnostics

  ()
Algernon Health (AGN:CSE; AGNPF:OTCQB; AGW0:XFRA) plans to rebrand to Grey Matters Health Inc. while advancing its Alzheimer's diagnostic strategy and U.S. clinic rollout.
Tags: Healthcare Services

Expert Investing Ideas

Streetwise Reader Icon Streetwise Key Charts
Pharma Biotech & Life Sci

Get Our Streetwise Reports' Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

Philly Biotech Co. Develops High-Potential Autoimmune Therapy Breakthrough

  ()
Cabaletta Bio Inc. (CABA:NASDAQ) pushes rese-cel CAR T program forward with strong clinical momentum, production scalability, and analyst-backed upside potential.
Tags: Biotechnology / Pharmaceuticals

The World's First AI Voice Detection For Drugs & Alcohol With Charts That Beckon Investors To Buy

Contributed Technical Analyst Opinion
  ()
Technical Analyst Stewart Thomson explains why he thinks MindBio Therapeutics Corp. (MBIO:CSE; MBQIF:OTCQB; WF6:Frankfurt) is a Speculative Buy.
Tags: Medical DevicesLife Sciences Tools & Diagnostics

Biotech Company Uncovers Breakthrough Canine Arthritis Treatment

  ()
Israeli co. Can-Fite BioPharma Ltd. (CANF:NYSEAmerican) teamed up with Vetbiolix to trial Piclidenoson for dogs, with Phase 2 results due Q3 2026. Yet, one analyst still rates the stock as a Hold. Read on to see why.
Tags: Biotechnology / Pharmaceuticals

Biotech Price Target Raised on Strong FSHD and DM1 siRNA Data

Research Report
  ()
Wedbush Securities raised its price target on Sarepta Therapeutics Inc. (SRPT:NASDAQ), following promising Phase 1/2 data for siRNA candidates SRP-1001 in FSHD and SRP-1003 in DM1, citing superior muscle concentration and a clean safety profile versus rival programs from Novartis and Dyne Therapeutics.
Tags: Biotechnology / Pharmaceuticals

Massachusetts Biotech Co. Finds High-Potential Muscle Treatment Breakthrough

  ()
Sarepta Therapeutics Inc.'s (SRPT:NASDAQ) early results reveal dose-dependent drug exposure and significant biomarker reductions for forms of muscular dystrophy.
Tags: Biotechnology / Pharmaceuticals